Medica are pleased to announce that Richard Jones has been appointed as Chief Financial Officer (CFO) and an Executive Director of the Board. Richard will succeed Tony Lee, who will step down as Finance Director, following the announcement on 11 March 2020 that he would leave after 10 years at the Company. Following a transition period, Richard will join the Company later in the year at a date to be announced in due course.

Richard brings with him 20 years’ extensive experience working with and in fast-growing healthcare businesses, nine of which as a proven CFO of two listed healthcare UK companies. Richard is currently CFO at Mereo BioPharma Group Plc and was previously CFO at Shield Therapeutics Plc. He is also currently a Non-Executive Director and Chair of Audit Committee at Alliance Pharma Plc. Richard, a Chartered Accountant, started his career with PwC and moved into investment banking where he specialised in the healthcare services sector, initially as a research analyst and then into corporate finance as Head of Healthcare at Investec.

Roy Davis, Chairman at Medica, said:

“I am delighted to announce that Richard Jones will join Medica as CFO and a member of the Board. We are confident that Richard’s experience as a listed company CFO, coupled with his background in healthcare as a research analyst and corporate finance director, will support our engagement with investors as we implement our growth strategy.”

Dr. Stuart Quin, Chief Executive Officer of Medica, added:

“Richard is well-known within the UK healthcare market and I am pleased that he has decided to join our team. Medica has ambitious plans to expand and diversify its service offering and Richard’s leadership will be important as we develop the internal finance function at Medica, as well as to shape new business opportunities that will enable future growth.”

Commenting on his appointment, Richard Jones said:

“I am excited to be joining Medica as CFO and to be returning to the healthcare services market. Medica has a great opportunity to continue to cement its leading position in the UK teleradiology market, as well as look to grow through new opportunities. I look forward to working the executive team on this next stage of development.”